pharmaphorum

AHA: MSD's oral PCSK9 matches injectables

MSD has fleshed out the results of phase 3 trials of its cholesterol-lowering, oral PCSK9 inhibitor, enlicitide decanoate, showing its efficacy was comparable to that of injectable alternatives. The ...
Pharmabiz

Novartis Leqvio shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Novartis announced positive results from V-DIFFERENCE, a phase IV study evaluating Leqvio (inclisiran) compared to placebo, both administered on top of individually optimized lipid-lowering therapy ...
Finanznachrichten

Novartis Pharma AG: Novartis Leqvio shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain 1 85% ...
The Independent

Groundbreaking cholesterol jab could revolutionise heart disease care

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
Yahoo Finance

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Basel, August 30, 2025 – Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® (inclisiran) compared to placebo, both administered on top of individually ...
manilatimes

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

Patients on Leqvio plus LLT were 43% less likely to experience muscle-related adverse events compared to those on placebo plus LLT1 Basel, August 30, 2025 - Novartis today announced positive results ...
Yahoo Finance

Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance

Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment. Novartis Pharmaceuticals Canada Inc.
WebMD

Leqvio for Hyperlipidemia

Sometimes diet and exercise are not enough to lower cholesterol levels. Many different medicine options exist, including Leqvio, which can be used alone or with other medicines to help people reach ...
AOL

Which Medicare part covers Leqvio?

Leqvio is a brand-name prescription medication containing the active ingredient inclisiran. A doctor or healthcare professional will administer the medication as an injection under the skin. Original ...
WebMD

Leqvio: New Injectable Option for Lowering Bad Cholesterol Without Statins

What Is Leqvio, and Why Does It Matter? Leqvio (inclisiran) is a prescription injection that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol, which is a ...
Pharm Exec

FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia

Leqvio's label update allows its use as a first-line monotherapy for LDL-C reduction in hypercholesterolemia, reflecting strong PCSK9-targeting evidence. The update addresses an unmet need, as many ...